NDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SYMFI LO (efavirenz; lamivudine; tenofovir disoproxil fumarate) by Viatris (2) is fixed-dose combination of antiviral drugs efv, 3tc, and tdf with antiviral activity against hiv-1 [see ]. First approved in 2018.
Drug data last refreshed 14m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMFI LO is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate for the treatment of HIV-1 infection. The three-drug combination provides complementary antiviral activity through inhibition of reverse transcriptase and integrase pathways. Patients take one tablet once daily as part of antiretroviral therapy regimens.
$0.135BPart D
PeakProduct is at peak sales with modest Part D volume (54 claims in 2023); commercial team size is likely stable or modest, suggesting optimized infrastructure rather than growth investment.
Mechanism of Action
fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYMFI LO roles focus on defending market share and optimizing compliance in an established HIV treatment segment rather than launching or expanding new indications. Career opportunities emphasize commercial execution, payer negotiation, and patient support program management in a mature, competitive therapeutic category.
Brand ManagerMedical Science Liaison
Worked on SYMFI LO at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.